Login to Your Account



Movetis Seeking €112.5M: Is End to Europe's IPO Drought Near?

By Cormac Sheridan


Wednesday, November 25, 2009

No Abstract

 

BioWorld International Correspondent

Movetis NV is testing the mettle of European life sciences investors with the sector's first sizeable initial public offering since the first quarter of 2008.

With a European product launch imminent, the company offers a far less risky proposition than most, however.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription